The main focus of my research program is the quality of care received by patients with cancer especially in regards to delivery of systemic therapy. I am also interested in understanding the evolution and dissemination of findings from randomized controlled trials in cancer.
Development and Validation of a Score to Predict Acute Care Use After Initiation of Systemic Therapy for Cancer.
JAMA Netw Open. 2019 Oct 02;2(10):e1912823
Ambulatory Toxicity Management (AToM) in patients receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer - a pragmatic cluster randomized trial protocol.
BMC Cancer. 2019 Sep 05;19(1):884
Estimating the optimal perioperative chemotherapy utilization rate for muscle-invasive bladder cancer.
Cancer Med. 2019 Aug 31;:
Cancer Med. 2019 Aug 12;:
Practices and opinions of specialized palliative care physicians regarding early palliative care in oncology.
Support Care Cancer. 2019 Jun 04;:
The association of continuity of care and cancer centre affiliation with outcomes among patients with cancer who require emergency department care.
CMAJ. 2019 Apr 23;191(16):E436-E445
User-Centered Design of a Web-Based Tool to Support Management of Chemotherapy-Related Toxicities in Cancer Patients.
J Med Internet Res. 2019 Mar 28;21(3):e9958
Ambulatory Toxicity Management (AToM) Pilot: results of a pilot study of a pro-active, telephone-based intervention to improve toxicity management during chemotherapy for breast cancer.
Pilot Feasibility Stud. 2019;5:39
Medical Oncologist, Princess Margaret Cancer Centre
Associate Professor of Medicine, University of Toronto
Clinical Lead, Quality Care and Access, Systemic Treatment Program, Cancer Care Ontario
Adjuct Scientist, Institute for Clinical Evaluative Sciences